Dunhill Financial, LLC Viracta Therapeutics, Inc. Transaction History
Dunhill Financial, LLC
- $215 Billion
- Q4 2024
Shares
1 transactions
Others Institutions Holding VIRX
# of Institutions
37Shares Held
4.52MCall Options Held
0Put Options Held
0-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.63MShares$32,5250.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA289KShares$5,7830.0% of portfolio
-
Aisling Capital Management LP New York, NY289KShares$5,7710.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny286KShares$5,7270.0% of portfolio
-
Black Rock Inc. New York, NY273KShares$5,4650.0% of portfolio
About Viracta Therapeutics, Inc.
- Ticker VIRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,558,200
- Market Cap $751K
- Description
- Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...